再鼎医药有限公司宣布，公司已签署一项合作协议。根据协议条款，再鼎医药将负责提供其靶向Dll3的抗体偶联药物（ADC），用于相关临床研究。而勃林格殷格翰将作为研究的申办方，并全面主导及监督日常临床运营工作的开展。
再鼎医药有限公司宣布，公司已签署一项合作协议。根据协议条款，再鼎医药将负责提供其靶向Dll3的抗体偶联药物（ADC），用于相关临床研究。而勃林格殷格翰将作为研究的申办方，并全面主导及监督日常临床运营工作的开展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.